ADAG
Adagene, Inc.
NASDAQ · Healthcare · Biotechnology · CN
$2.29
+11.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.04
From 52W high−52.09%
Volume306369.00
Market cap$153.76M
P/E (TTM)—
P/S (TTM)16.5x
Div yield—
Key dataOct 19, 2026
Open
$2.04
From 52W high
−52.09%
Volume
306369.00
Market cap
$153.76M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.2x
P/E (TTM)
—
RSI (14)
29.4
MomentumView details →
1D Return
+11.17%
YTD Return
+14.55%
SummaryUpdated Jun 1, 2026
Adagene Inc. (NASDAQ:ADAG) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Suzhou, China. The company went public on February 9, 2021, and focuses on developing innovative monoclonal antibody therapies for cancer treatment. Adagene specializes in creating next-generation antibody drugs using proprietary platforms to address limitations of existing cancer immunotherapies. The company operates primarily in the oncology space, developing treatments for both solid tumors and blood cancers.
Similar companies
Latest newsMore news →
China's National Medical Products Administration approved Adagene's investigational new drug application for ADG138, a double-masked HER2xCD3 bispecific T-cell engager, with a Phase 1 study in advanced solid tumors expected to begin in China in Q4 2026.28d agoThird Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene for the development of masked CD3 T cell engagers utilizing Adagene's SAFEbody technology.40d ago